BioDelivery Sciences International Inc (BDSI) Stock
BDSI is no longer traded. BioDelivery Sciences International was delisted from the Nasdaq in March 2022.
Prices on this page are historical; the last trade was March 22, 2022 at $5.59.
BioDelivery Sciences International stock price history
BDSI final trading statistics
- Final close
- $5.59
- Final trading day
- Mar 22, 2022
- Market cap at delisting
- $577.05M
- Shares outstanding
- 103.23M
- Final 52-week range
- $2.50 – $5.62
- Avg. volume (final 3 mo.)
- 3,283,072
- All-time high (split-adj.)
- $18.15 · Sep 2014
- All-time low (split-adj.)
- $0.78 · Dec 2011
- Return since IPO
- +69.4%
- Beta
- 0.56
- Book value / share
- $1.90
- Price / book
- 2.94
BioDelivery Sciences International annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $166.70M | $84.9M | $0.83 |
| FY2020 | $156.47M | $25.7M | $0.25 |
| FY2019 | $111.39M | -$15.3M | -$0.19 |
| FY2018 | $55.64M | -$33.9M | -$0.76 |
| FY2017 | $61.98M | $5.3M | -$0.19 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About BioDelivery Sciences International Inc
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
BioDelivery Sciences International stock FAQ
What happened to BioDelivery Sciences International stock?
BioDelivery Sciences International stock was delisted from the Nasdaq. Its final close was $5.59 on March 22, 2022.
Is BDSI stock still trading?
No. BDSI was delisted from the Nasdaq in March 2022 and no longer trades on a U.S. exchange.
What was the last price of BDSI stock?
BDSI closed at $5.59 on its final trading day, March 22, 2022, for a market value of about $577.05M.
What were BioDelivery Sciences International's revenue and earnings in its last full fiscal year?
BioDelivery Sciences International reported revenue of $166.70M and net income of $84.9M in fiscal 2021, its last full year as a public company.
When did BioDelivery Sciences International go public?
BioDelivery Sciences International Inc stock began trading on July 25, 2002.